Small Molecule Drug Discovery Market By Discovery Stage (Target Identification and Validation, Hit Identification, Hit-to-Lead, Lead Optimization, Preclinical Candidate Selection); By Technology and Service (High-Throughput Screening, Structure-Based Drug Design, Fragment-Based Drug Discovery, Virtual Screening and AI-Enabled Design, Medicinal Chemistry, ADME and Toxicology Support); By Therapeutic Area (Oncology, Infectious Diseases, Neurology and Psychiatry, Cardiovascular and Metabolic Disorders, Immunology, Rare Diseases, Others); By End User (Pharmaceutical Companies, Biotechnology Companies, CROs and CRDMOs, Academic and Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Small Molecule Drug Discovery Market: AI-Enabled Chemistry, Targeted Oral Therapies, and Patent-Cliff Pressure Rebuild Pharma’s Core Discovery Engine

The Global Small Molecule Drug Discovery Market is set to expand from USD 68.54 billion in 2025 to USD 128.6 billion by 2032, growing at a CAGR of 9.4%.

 

The Small Molecule Drug Discovery Market remains central to pharmaceutical R&D because small molecules still solve problems that many larger modalities cannot address at scale. Their commercial value is driven by oral bioavailability, lower manufacturing complexity, intracellular target engagement, blood–brain barrier penetration, and suitability for chronic disease management where dosing convenience and cost considerations are critical. While biologics, RNA therapies, peptides, and cell therapies are expanding the therapeutic toolkit, small molecules continue to anchor the largest disease areas in medicine: infections, oncology, cardiovascular disease, metabolic disorders, neurology, immunology, and rare diseases.

 

Small molecules still carry the largest installed base in global pharmacotherapy. Frontiers in Drug Discovery notes that more than 90% of marketed drugs are small molecules, and Reuters reported that more than two-thirds of total FDA new-drug approvals in 2025 were small-molecule drugs. FDA CDER approved 46 novel drugs in 2025, including 34 new molecular entities and 12 biologics. Of these, 20 drugs, or 43%, were first-in-class; 23, or 50%, received orphan-drug designation; 72% used at least one expedited program; 85% were approved in the first review cycle; and 70% were approved first in the United States. These figures show that small molecules remain commercially central, but the most valuable discovery programs are increasingly differentiated by novelty, rare-disease positioning, biomarker strategy, and regulatory speed.

 

Approval Momentum Shows Small Molecules Are Still Core to Innovation

The 2025 FDA approval landscape indicates that small molecules continue to maintain a dominant position despite the growth of biologics and advanced modalities. Industry tracking identified 31 small-molecule approvals among 46 FDA CDER novel drug approvals in 2025, while Reuters reported that small molecules accounted for more than 67% of total FDA new drug approvals when CDER approvals were assessed alongside cell and gene therapies. The 2024 benchmark shows a consistent pattern, with the FDA CDER approving 50 novel drugs and small molecules representing approximately 62%–64% of approvals depending on classification methodology.

Recent approvals show where small-molecule discovery is creating new value. Rezdiffra, or resmetirom, became the first FDA-approved medication for noncirrhotic NASH/MASH with moderate-to-advanced fibrosis in 2024. Voranigo, or vorasidenib, became the first FDA-approved systemic therapy for Grade 2 IDH-mutant astrocytoma or oligodendroglioma following surgery. Revuforj, or revumenib, became the first approved menin inhibitor for relapsed or refractory acute leukemia with KMT2A translocation and later gained an additional FDA approval for susceptible NPM1-mutated relapsed or refractory AML. These approvals show that small molecules remain highly relevant when they are matched to well-defined biology, genetic alteration, tissue access needs, and oral treatment convenience.

 

Clinical Development Share Is Declining, but Small Molecules Still Lead Programs

Small molecules are still the largest clinical-development modality, but their relative share is falling as other modalities expand. A 2025 Nature Communications analysis studied 20,398 clinical development programs covering 9,682 molecular entities across 910 WHO ICD-11 disease indications from 2001 to 2023. The study found that the share of small-molecule drugs among unique clinically tested molecular entities declined from 66.3% at the start of the 21st century to 46.6% recently. By clinical development programs, small molecules declined from 72.4% to 57.2%.

This shift does not weaken the opportunity for small molecules but redefines its nature. Broad, undifferentiated chemistry programs are becoming increasingly difficult to justify, while development is shifting toward target-validated, structure-guided, biomarker-selected, orally optimized, and computationally driven small molecules. Oncology, immunology, central nervous system disorders, metabolic diseases, and anti-infective indications remain central, as many therapeutically relevant targets are intracellular enzymes, receptors, protein–protein interaction interfaces, transcriptional regulators, kinases, epigenetic modifiers, or RNA-associated structures.

Attrition remains a significant challenge in oncology drug development. A Nature Communications analysis reports overall recent success rates in the mid-single-digit range, with oncology programs demonstrating particularly high failure rates. BIO/Informa data further highlight the importance of precision development strategies, showing that programs incorporating patient-preselection biomarkers achieve a Phase I–to–approval likelihood of approximately 15.9%, compared with 7.6% for non-biomarker–guided programs. These findings reinforce the growing emphasis on genetically defined indications, companion diagnostics, pharmacodynamic biomarkers, and early patient stratification.

 

Disease Areas Where Small Molecules Still Create the Strongest Discovery Value

Small molecules create the strongest discovery value where disease biology requires oral dosing, intracellular target access, tissue penetration, scalable manufacturing, or blood-brain barrier exposure. This is why the category remains strategically important even as biologics, peptides, RNA therapies, and cell therapies expand across pharma pipelines. The highest-impact opportunities are concentrated in infectious diseases, oncology, neurology, cardiology, and metabolic disorders.

In infectious diseases, small molecules remain essential because antibiotics and antivirals need to be manufactured at scale, distributed globally, and administered quickly in acute-care or outpatient settings. Penicillin-class antibiotics, macrolides, fluoroquinolones, azoles, antiretrovirals, hepatitis C antivirals, and oral COVID-19 antivirals such as Paxlovid show why small molecules remain hard to replace in infection control. WHO estimates that bacterial antimicrobial resistance was directly responsible for 1.27 million deaths in 2019 and contributed to 4.95 million deaths, creating a strong need for new antibacterial scaffolds, beta-lactamase inhibitor combinations, antifungals, and antivirals.

In oncology, small molecules remain central because many cancer-driving targets sit inside the cell. Kinases, epigenetic proteins, mutant enzymes, DNA repair proteins, transcriptional regulators, menin, IDH, KRAS, PARP, BTK, JAK, ALK, EGFR, BRAF, and PI3K-related pathways are all commercially important small-molecule target classes. IARC estimated nearly 20 million new cancer cases and 9.7 million cancer deaths in 2022, with new cancer cases projected to exceed 35 million by 2050. This burden supports continued discovery of targeted inhibitors, molecular glues, PROTAC degraders, covalent inhibitors, resistance-mutation drugs, and CNS-penetrant oncology therapies for brain metastases and primary brain tumors.

In neurology and psychiatry, small molecules remain especially important because many treatments must cross the blood-brain barrier. The blood-brain barrier limits entry of many large molecules, making small-molecule design central to depression, anxiety, schizophrenia, epilepsy, migraine, Parkinson’s disease, Alzheimer’s disease, sleep disorders, and pain. WHO reported that more than 3 billion people worldwide were living with a neurological condition in 2021, while nearly 1.1 billion people were living with a mental disorder. This creates a large discovery opportunity for oral CNS-active drugs with better selectivity, fewer side effects, and improved brain exposure.

In cardiology and metabolic disease, small molecules dominate because treatment is often chronic, high-volume, and cost-sensitive. Statins, antihypertensives, antiplatelet drugs, oral anticoagulants, SGLT2 inhibitors, GLP-1-related oral candidates, lipid-lowering agents, and diabetes drugs show how small molecules can scale across very large patient populations. WHO estimated that cardiovascular diseases caused 19.8 million deaths in 2022, representing about 32% of global deaths, while 1.4 billion adults aged 30–79 were living with hypertension in 2024. IDF estimated that 589 million adults aged 20–79 were living with diabetes in 2024, with the number projected to rise to 853 million by 2050. These figures explain why companies continue to invest in oral, manufacturable, long-duration small molecules for cardiometabolic risk reduction.

These disease areas show that small molecule discovery is still commercially durable because it aligns with major global health burdens and practical treatment needs. The next wave is not defined by conventional high-throughput screening alone. It is being shaped by AI-enabled design, structure-based chemistry, biomarker-selected oncology, new anti-infective mechanisms, CNS-penetrant molecules, targeted protein degradation, and oral alternatives to injectable therapies.

 

Data Scale Is Becoming a Competitive Advantage

Small-molecule discovery is no longer limited by whether companies can synthesize compounds; it is increasingly limited by whether they can choose better targets, predict better chemistry, and generate decision-quality data faster. Public and proprietary datasets now shape hit finding, virtual screening, target assessment, and structure-activity relationship design.

ChEMBL release 36 reported access to 2.8 million distinct compounds and 17,803 drug targets. DrugBank 6.0 has grown into a major knowledgebase for drug-target and related pharmaceutical data and averages more than 30 million views per year. PubChem has become one of the largest public chemical information resources, supporting structure search, bioactivity lookup, virtual screening, and cheminformatics workflows. These public resources are now combined with proprietary assay data, electronic lab notebooks, high-throughput screening output, cryo-EM structures, AlphaFold-informed protein models, clinical-genomic datasets, and automated synthesis feedback loops.

The market opportunity is therefore expanding beyond conventional medicinal chemistry services. Companies that can integrate target biology, structural biology, generative chemistry, ADMET prediction, automated synthesis, pharmacology, and clinical translation are better positioned than firms that offer only isolated chemistry capacity.

 

AI and Automation Are Moving From Pilot Projects to Pharma Partnerships

Artificial intelligence has become one of the most active investment themes in small-molecule drug discovery; however, its primary commercial value lies less in broad molecule generation and more in accelerating design–make–test–analyze cycles, improving prediction of ADMET properties, enhancing target–ligand interaction modeling, reducing synthesis bottlenecks, and enabling earlier identification of developability risks.

Bayer and Iambic announced a 2026 collaboration focused on AI-driven small molecule discovery, with Bayer using Iambic’s platform to address hard-to-drug targets. Takeda entered a separate multi-year Iambic collaboration valued at more than USD 1.7 billion to use AI for small-molecule drug design in cancer and gastrointestinal diseases. Reuters reported that Iambic’s platform combines AI predictions with automated laboratories and aims to compress the traditional six-year discovery-to-clinic timeline to less than two years.

Similar investment activity is reinforcing this direction. Excelsior Sciences raised USD 95 million in 2025 to advance AI-enabled small-molecule chemistry and automated synthesis platforms. Amgen announced a USD 125 million expansion of its South San Francisco research center in 2026, integrating medicinal chemistry, biology, protein science, automation, and data science to accelerate discovery workflows. Collectively, these developments indicate a shift from AI as a supplementary tool toward AI-enabled laboratory infrastructure in drug discovery.

 

Oncology Remains the Most Important High-Value Discovery Area

Oncology continues to anchor high-value small molecule discovery because many cancer drivers remain enzyme-based, mutation-defined, pathway-specific, or intracellular. WHO/IARC estimated about 20 million new cancer cases and nearly 10 million cancer deaths in 2022, with new cancer cases projected to exceed 35 million by 2050. This burden supports sustained investment in kinase inhibitors, epigenetic drugs, menin inhibitors, KRAS-pathway agents, IDH inhibitors, PI3K/AKT/mTOR pathway drugs, PARP inhibitors, targeted protein degraders, and RNA-targeting small molecules.

Precision oncology has made the small-molecule oncology market more segmented while also increasing its clinical defensibility. Treatment guidelines in non-small cell lung cancer are increasingly driven by actionable biomarkers, including EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, KRAS G12C, HER2, and related genomic alterations. This creates a clear commercial rationale for small molecules that can target intracellular oncogenic drivers and be integrated with molecular diagnostic testing.

Oncology discovery programs are now evaluated beyond potency alone. Key differentiating parameters include selectivity, coverage of resistance mutations, central nervous system penetration, combination potential, therapeutic index, oral administration convenience, biomarker definition, and suitability for earlier lines of therapy.

 

Cardiometabolic and Oral Obesity Drugs Reinforce the Pill Advantage

Cardiometabolic disease is another major growth field because small molecules can support chronic oral therapy, large-patient populations, and scalable manufacturing. WHO reports that noncommunicable diseases account for 74% of global deaths, with cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes driving most of the burden. This creates long-term demand for orally administered small molecules in hypertension, dyslipidemia, diabetes, obesity, chronic kidney disease, heart failure, metabolic liver disease, and thrombosis.

The oral GLP-1 competitive landscape has reinforced the strategic importance of small-molecule convenience in markets otherwise dominated by injectable biologics and peptides. Novo Nordisk projects that oral weight-loss therapies could account for more than one-third of the global GLP-1 obesity market by 2030, while Eli Lilly, Novo Nordisk, AstraZeneca, Structure Therapeutics, Merck, Pfizer-linked assets, Roche, Viking Therapeutics, Innovent, and other developers are advancing oral obesity and metabolic candidates across clinical and commercial stages. The key implication is that small molecules can remain competitive in settings where patient preference, ease of administration, cost efficiency, and scalability are as critical as clinical efficacy.

 

Anti-Infectives and AMR Keep Small Molecule Discovery Clinically Essential

Anti-infectives remain an essential but economically difficult area for small molecule discovery. WHO estimates that bacterial antimicrobial resistance was directly responsible for 1.27 million global deaths in 2019 and associated with 4.95 million deaths. This makes new antibacterial small molecules a public-health necessity, but the commercial model remains challenging because antibiotics are used sparingly, treatment courses are short, and stewardship programs intentionally restrict volume.

This creates a specialized market for companies that can develop differentiated agents against resistant Gram-negative pathogens, tuberculosis, drug-resistant gonorrhea, fungal infections, and viral diseases. The opportunity is not broad-spectrum volume alone; it is activity against priority pathogens, resistance-mechanism coverage, rapid diagnostics compatibility, and policy-supported access models.

 

Patent Cliff Pressure Is Increasing Demand for Replacement Pipelines

The small molecule discovery market is also being shaped by the 2025–2030 patent cliff. Several major branded drugs are approaching loss of exclusivity, and small molecules face faster generic erosion than biologics because abbreviated approval pathways and chemical manufacturing are more mature. U.S. pharmaceutical revenue at risk between 2025 and 2030 has been estimated in the hundreds of billions of dollars, with diabetes, oncology, immunology, and cardiovascular franchises among the affected areas.

This creates pressure on large pharma to rebuild pipelines through internal discovery, AI partnerships, licensing, and early-stage acquisitions. The result is visible in recent deal activity. Novartis entered a potential USD 1.9 billion collaboration with Antares Therapeutics in 2026 for cancer therapies against historically hard-to-drug targets. Takeda’s more than USD 1.7 billion Iambic collaboration and Bayer’s Iambic partnership show that large pharma is using AI-enabled discovery alliances to reduce the replacement gap created by exclusivity losses.

 

Outsourcing and CRDMO Platforms Are Capturing More Small-Molecule Work

Small molecule discovery is also benefiting CRO, CDMO, and CRDMO providers because many biotech and pharma companies want flexible chemistry, scale-up, and development capacity without building every capability internally. WuXi AppTec reported that its 2025 small molecule development and manufacturing revenue rose 11.4% year over year to RMB 19.92 billion. The company added 839 new molecules to its small molecule D&M pipeline, reaching 3,452 molecules by year-end, including 83 commercial projects, 91 Phase III projects, 377 Phase II projects, and 2,901 Phase I and preclinical-stage projects.

This data shows why outsourcing is no longer only a cost-saving decision. Small molecule companies increasingly need integrated discovery-to-manufacturing partners that can support medicinal chemistry, process chemistry, analytical development, toxicology, GMP manufacturing, and lifecycle scale-up. The “follow the molecule” model is becoming more important because discovery quality, manufacturability, impurity control, and supply resilience are now linked earlier in development.

 

Regional Outlook

North America leads the market because the U.S. remains the strongest approval, financing, and innovation hub. FDA CDER’s 46 novel approvals in 2025, 85% first-cycle approval rate, and 70% first-in-U.S. approval share show why the U.S. remains the most important commercialization market for novel small molecules. The region also benefits from AI-biotech funding, academic spinouts, venture-backed discovery companies, and large pharma partnerships.

Europe remains a major discovery and regulatory region. EMA recommended 104 medicines for approval in 2025, including 38 medicines with a new active substance. Europe also has strong medicinal chemistry, structural biology, CRO, biotech, and translational research infrastructure. ChEMBL, hosted by EMBL-EBI, is a major European public bioactivity resource used globally for drug discovery and target prioritization. European activity is strongest in oncology, immunology, neuroscience, rare disease, anti-infectives, and data-driven translational medicine.

Asia Pacific is the fastest-expanding strategic region because of China’s chemistry capacity, Japan’s pharma innovation base, India’s API and CDMO scale, Singapore’s AI-for-science ecosystem, and rising regional biotech financing. The Nature Communications clinical-development dataset showed Asia accounted for 19.5% of clinical trial data distribution, compared with 32.5% for North America and 39.7% for Europe. China and India are especially important for chemistry services, API manufacturing, generics, and increasingly innovation-led small molecule development. Japan remains important through companies such as Takeda, Daiichi Sankyo, Astellas, and Chugai-linked programs, while Singapore is becoming more visible in AI-enabled laboratory infrastructure.

 

Competitive Landscape

The competitive landscape includes large pharmaceutical companies, AI-native discovery companies, specialist biotech firms, CRO/CDMO/CRDMO platforms, database providers, and enabling-technology suppliers. Large pharma players such as AstraZeneca, Novartis, Merck, Pfizer, Eli Lilly, Novo Nordisk, Takeda, Bayer, Amgen, Bristol Myers Squibb, GSK, Roche, and Sanofi continue to invest in small molecule programs across oncology, cardiometabolic disease, immunology, neuroscience, and anti-infectives.

AI and platform companies are becoming more important. Iambic Therapeutics is now visible through Bayer and Takeda partnerships. Excelsior Sciences is targeting AI-compatible automated chemistry. Schrödinger, Recursion, Exscientia, Insilico Medicine, BenevolentAI, Deep Origin, ChemLex, and related companies are working across structure-based design, generative chemistry, automated screening, and translational prediction. CRDMO providers such as WuXi AppTec, Symeres, Cambrex, Charles River, Thermo Fisher/Patheon, Sai Life Sciences, Neuland Labs, and other regional players are capturing outsourced chemistry, discovery, process development, and manufacturing demand.

 

Analyst Insight

The Small Molecule Drug Discovery Market is not being replaced by biologics; it is being upgraded. Small molecules still dominate marketed medicines and recent approvals, but the next phase of growth will favor programs with better biology, cleaner target validation, stronger ADMET prediction, defined biomarkers, faster synthesis cycles, and clearer clinical differentiation.

The strongest opportunities are in oncology, cardiometabolic disease, CNS disorders, immunology, anti-infectives, rare diseases, targeted protein degradation, RNA-targeting small molecules, covalent inhibitors, molecular glues, and oral alternatives to injectable therapies. AI will not automatically fix the discovery productivity problem, but it is becoming valuable where it improves molecule quality, reduces unnecessary synthesis, predicts liabilities earlier, and connects chemistry with biology and clinical data.

 

Small Molecule Drug Discovery Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 68.54 Billion
Revenue Forecast in 2032	USD 128.6 Billion
Overall Growth Rate	CAGR of 9.4% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Billion and CAGR (2026–2032)
Segmentation	By Discovery Stage, By Technology and Service, By Therapeutic Area, By End User, By Geography
By Discovery Stage	Target Identification and Validation, Hit Identification, Hit-to-Lead, Lead Optimization, Preclinical Candidate Selection
By Technology and Service	High-Throughput Screening, Structure-Based Drug Design, Fragment-Based Drug Discovery, Virtual Screening and AI-Enabled Design, Medicinal Chemistry, ADME and Toxicology Support
By Therapeutic Area	Oncology, Infectious Diseases, Neurology and Psychiatry, Cardiovascular and Metabolic Disorders, Immunology, Rare Diseases, Others
By End User	Pharmaceutical Companies, Biotechnology Companies, CROs and CRDMOs, Academic and Research Institutes
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	United States, Canada, United Kingdom, Germany, France, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, Mexico, Saudi Arabia, United Arab Emirates, and South Africa
Market Drivers	Expansion of AI-enabled chemistry and virtual screening; rising demand for targeted and orally administered therapies; increasing patent-cliff pressure on major pharmaceutical companies; continued investment in oncology, cardiometabolic, CNS, and anti-infective pipelines; greater outsourcing to integrated CRO and CRDMO platforms
Key Market Opportunities	Targeted protein degradation, molecular glues, RNA-targeting compounds, CNS-penetrant therapies, oral alternatives to injectable drugs, automated synthesis, and biomarker-guided precision medicine
Customization Option	Available upon request